-
Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceuticals for Prescription Drug Co-Marketing
•
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO) collaboration agreement with Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607; SPH). This new agreement follows the success of their initial collaboration in 2020 and aims to further enhance the co-marketing efforts for prescription drugs. Building…
-
Eslicarbazepine Makes First Appearance in China at Sichuan University’s West China Lecheng Hospital
•
Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first prescribed at the West China Lecheng Hospital of Sichuan University late last month. This epilepsy therapy marks the first special novel drug program implemented through the “first pilot, first trial” policy of the Boao Lecheng…
-
Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market
•
Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of Japan-based Sumitomo Pharma, has expressed strong optimism about the company’s prospects in the local market in an interview with Shanghai Daily. Koketsu emphasized that China, as the world’s second-largest pharmaceutical market, holds strategic significance for…
-
Health Canada Approves Pfizer and Sumitomo Pharma’s Myfembree for Endometriosis Pain Management
•
Health Canada has granted regulatory approval to Pfizer (NYSE: PFE) and Sumitomo Pharma (TYO: 4506) for their women’s health product Myfembree (relugolix + estradiol + norethindrone acetate). The approval is for the management of moderate-to-severe pain associated with endometriosis in pre-menopausal women, supported by late-stage data from multiple trials. Previous…
-
Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials
•
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have revealed a setback in late-stage clinical trials for the potential first-in-class trace amine-associated receptor 1 (TAAR1) agonist, ulotaront, as a treatment for schizophrenia. Topline data from the Phase III DIAMOND 1 and DIAMOND 2 studies…
-
Sumitomo Pharma to Invest $30 Million in China for New Product Development
•
Japan-based Sumitomo Pharma (TYO: 4506), through its China unit, is planning a significant investment of USD 30 million in the China market, as reported by Shine. This investment, as stated by Yoshitaka Koketsu, president and CEO of Sumitomo Pharma (China) Co., Ltd, is aimed at developing and launching new products…
-
Sumitomo Pharma Secures Rights to Vibegron for Asian Markets
•
Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical Co., Ltd, focusing on the over-active bladder (OAB) therapy Gemtesa (vibegron). This strategic agreement grants Sumitomo development, manufacturing, and commercialization rights to vibegron in key Asian markets, including Taiwan and Hong Kong in China, Singapore,…
-
Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China
•
Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company in Shanghai. The collaboration aims to promote Lonasen (blonanserin) and Latuda (lurasidone), both antipsychotic medications, in the Chinese market. Financial details of the partnership were not disclosed. Epidemiological ContextAccording to the latest epidemiological survey in…
